ZIPRASIDONE HYDROCHLORIDE | N021483 | PFIZER INC
| Trial | Phase | Status | Sponsor | Enrollment | Dates |
|---|---|---|---|---|---|
| Phase 1 | Active | University of Arizona | 24 | 2017-11-20 → 2027-02-10 | |
| Phase 4 | Completed | Massachusetts General Hospital | 20 | 2002-03 → 2004-12 | |
| Phase 2 | Completed | Georgetown University | 43 | 2007-11 → 2011-03 | |
| Phase 4 | Completed | Northwell Health | 357 | 2006-05 → 2011-01 | |
| Phase 4 | Completed | Creighton University | 80 | 2002-12 → 2005-04 | |
| Phase 3 | Completed | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 169 | 2006-03 → 2008-01 | |
| Phase 1 | Completed | Dr. Reddy's Laboratories Limited | 56 | 2004-11 → 2005-01 | |
| Phase 4 | Completed | The Medical Research Network | 30 | 2005-02 → 2008-02 | |
| Phase 4 | Completed | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 112 | 2003-04 → 2007-02 | |
| Phase 2 | Completed | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | 60 | 2004-03 → 2006-04 |
Source: ClinicalTrials.gov. Trials matched by ingredient name; data refreshed each weekday and may lag the registry.
12 active API suppliers hold Drug Master Files for this ingredient.
Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.
| Date | Submission | Document |
|---|---|---|
| Mar 2, 2017 | SUPPL -15 | View Letter (PDF) |
| Aug 24, 2015 | SUPPL -14 | View Letter (PDF) |
| Dec 11, 2014 | SUPPL -13 | View Letter (PDF) |
| Aug 16, 2013 | SUPPL -10 | View Letter (PDF) |
| Jul 5, 2013 | SUPPL -7 | View Letter (PDF) |
| Mar 5, 2013 | SUPPL -9 | View Letter (PDF) |
| Dec 7, 2010 | SUPPL -5 | View Letter (PDF) |
| Nov 24, 2009 | SUPPL -3 | View Letter (PDF) |
| Apr 5, 2006 | ORIG -1 | View Letter (PDF) |
Source: Drugs@FDA application documents.
No patent or exclusivity listings for this strength.